These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2920497)

  • 21. Indirect-response model for the time course of leukopenia with anticancer drugs.
    Minami H; Sasaki Y; Saijo N; Ohtsu T; Fujii H; Igarashi T; Itoh K
    Clin Pharmacol Ther; 1998 Nov; 64(5):511-21. PubMed ID: 9834043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.
    Lowis SP; Pearson AD; Newell DR; Cole M
    Cancer Res; 1993 Oct; 53(20):4881-9. PubMed ID: 8402676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer.
    Kunitoh H; Watanabe K
    J Clin Oncol; 1994 Jan; 12(1):83-9. PubMed ID: 8270989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study.
    Thompson DS; Hainsworth JD; Hande KR; Holzmer MC; Greco FA
    J Clin Oncol; 1993 Jul; 11(7):1322-8. PubMed ID: 8315429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.
    Wilson WH; Jamis-Dow C; Bryant G; Balis FM; Klecker RW; Bates SE; Chabner BA; Steinberg SM; Kohler DR; Wittes RE
    J Clin Oncol; 1995 Aug; 13(8):1985-94. PubMed ID: 7636539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of the variability of etoposide pharmacokinetics in children.
    Boos J; Real E; Schulze-Westhof ; Wolff J; Euting T; Jürgens H
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):495-7. PubMed ID: 1490803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer.
    Miller AA; Tolley EA; Niell HB; Griffin JP; Mauer AM
    J Clin Oncol; 1993 Jun; 11(6):1179-88. PubMed ID: 8388920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
    Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Relations between hematological toxicity and total and free plasma levels of etoposide in daily oral administration].
    Lavit M; Chevreau C; Chatelut E; De Fenin V; Lochon I; Houin G; Bugat R; Canal P
    Bull Cancer; 1995 Aug; 82(8):660-4. PubMed ID: 7492822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
    Yong WP; Desai AA; Innocenti F; Ramirez J; Shepard D; Kobayashi K; House L; Fleming GF; Vogelzang NJ; Schilsky RL; Ratain MJ
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):811-9. PubMed ID: 17308893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacokinetic aspects of oral administration of etoposide].
    Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
    Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration.
    Hande K; Messenger M; Wagner J; Krozely M; Kaul S
    Clin Cancer Res; 1999 Oct; 5(10):2742-7. PubMed ID: 10537337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of grapefruit juice intake on etoposide bioavailability.
    Reif S; Nicolson MC; Bisset D; Reid M; Kloft C; Jaehde U; McLeod HL
    Eur J Clin Pharmacol; 2002 Oct; 58(7):491-4. PubMed ID: 12389073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
    Mick R; Vokes EE; Lestingi TM; Gray-Stern W; Fleming GF; Schilsky RL; Ratain MJ
    Clin Pharmacol Ther; 1996 Mar; 59(3):349-59. PubMed ID: 8653998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day.
    Aydiner A; Koyuncu H; Tas F; Topuz E; Disci R
    Int J Clin Pharmacol Res; 2000; 20(1-2):21-30. PubMed ID: 11146899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New perspectives on the toxicity of etoposide.
    Kobayashi K; Ratain MJ
    Semin Oncol; 1992 Dec; 19(6 Suppl 13):78-83. PubMed ID: 1492230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting etoposide toxicity: relationship to organ function and protein binding.
    Joel SP; Shah R; Clark PI; Slevin ML
    J Clin Oncol; 1996 Jan; 14(1):257-67. PubMed ID: 8558207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
    Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.